Pfizer's cancer drug Inlyta has been approved by the US Food and Drug Administration to be used in treating patients with advanced kidney cancer.
The health regulator said that the drug can be used to treat patients who do not respond to any other drugs currently available in treating advanced kidney cancer.
AdvertisementThe director of the FDA's office of oncology products, Richard Pazdur announced that Inlyta was the seventh drug approved by the agency to treat advanced kidney cancer and the latest approval will provide patients with multiple treatment options.
While Pfizer will be hoping that the approval will help boost their flagging sales following continued poor performance of its cholesterol drug Lipitor, market analysts said that Inlyta will struggle to gain a foothold in a congested market and predicted peak sales of $600 million.
P Doctors Save Stillborn Baby Who Had No Blood in His Body Sharp Drop Observed in Number of Lower Limb Amputations Due to Diabetes M
You May Also Like